MADISON - FluGen Inc., a biotechnology company
developing a “universal” influenza vaccine, announced Tuesday it
completed a $12 million series A financing.
Venture Investors LLC, the Wisconsin Alumni
Research Foundation, the state of Wisconsin Investment Board,
and other new investors participated in this first institutional
financing of the company, along with many of FluGen’s existing
investors led by Knox LLC.
Funds raised will support the continued
development of FluGen’s lead universal influenza vaccine
candidate, REDEE FLU, including completion of an initial human
clinical trial and the preparation of a quadrivalent vaccine